---
title: "Garden Biopharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 96.5114 million yuan, a year-on-year increase of 5.5%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236369613.md"
description: "Garden Biopharmaceutical released its Q1 2025 earnings report, with operating revenue of 326 million yuan, a year-on-year decrease of 1.18%; net profit attributable to the parent company of 96.5114 million yuan, a year-on-year increase of 5.5%; net profit after deducting non-recurring gains and losses of 88.1384 million yuan, a year-on-year increase of 44.42%; basic earnings per share of 0.18 yuan/share"
datetime: "2025-04-17T08:34:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236369613.md)
  - [en](https://longbridge.com/en/news/236369613.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236369613.md)
generator: "portal-rs"
---

# Garden Biopharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 96.5114 million yuan, a year-on-year increase of 5.5%

According to the Zhitong Finance APP, Garden Biopharmaceutical (300401.SZ) released its first-quarter report for 2025. The company's operating revenue for the first quarter of 2025 was 326 million yuan, a year-on-year decrease of 1.18%; the net profit attributable to shareholders of the listed company was 96.5114 million yuan, a year-on-year increase of 5.50%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 88.1384 million yuan, a year-on-year increase of 44.42%; basic earnings per share were 0.18 yuan/share

### Related Stocks

- [300401.CN](https://longbridge.com/en/quote/300401.CN.md)

## Related News & Research

- [TRMED: Commercial production ramp-up and strategic partnerships drive growth in isotope supply](https://longbridge.com/en/news/297267109.md)
- [RUBBER-Japan futures rise on supply concerns in top producing regions](https://longbridge.com/en/news/297141554.md)
- [SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data](https://longbridge.com/en/news/297303959.md)
- [08:10 ETTruvant Acquires New Jersey-Based Multi-Pak Packaging, a Specialist in Vitamins, Supplements and OTC](https://longbridge.com/en/news/296912238.md)
- [Thor Medical launches commercial operations at AlphaOne as isotope demand builds](https://longbridge.com/en/news/297270361.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**